Campbell, CA, April 29, 2019 – Dark Horse Consulting Group, the leading global consultancy practice specializing in cell and gene therapy product development, recently participated in the 2019 American Society of Gene and Cell Therapy 22nd Annual Meeting during April 29- May 2, 2019 in Washington, D.C.
Katy Spink, Ph.D., Managing Partner and COO of Dark Horse Consulting Group, presented an oral communication in the ‘Industry Perspective on CMC Challenges for Cell and Gene Modified Cell Therapy Products’ session during the Pre-Approval Commercialization workshop on ‘Clinical Path Toward Commercialization’ on Sunday April 29th. Dr Spink also co-chaired a session on Thursday May 2nd entitled ‘Commercializing Gene and Cell Therapies – Planning for Post-Approval Success and Pitfalls to Avoid’.
“The ASGCT meeting is one the world’s premier events in the cell & gene therapy calendar, and we are proud to have contributed to a very successful meeting in Washington,” said Katy Spink, Ph.D., Managing Partner and COO of Dark Horse Consulting.
The American Society of Cell and Gene Therapy Annual meeting is a four-day conference featuring presentations by leading companies and academic institutions working in the field. This Annual meeting brings together top decision-makers in the industry with researchers and clinical experts from around the globe, fostering key partnerships and advancing the industry to ultimately bring more cures to patients.
About Dark Horse Consulting Group
Dark Horse Consulting Group specializes in the development of cell and gene therapy products. All of our consultants have deep cell and gene therapy industry experience, spanning diverse functions including process development, device development, manufacturing, quality, regulatory, program management, business development, strategy, and financing/investor relations. Many of our consultants also bring experience from adjacent more mature sectors, including traditional biologics, small molecules, medical devices, and management consulting. As a result, we deeply understand the unique challenges faced by cell and gene therapy developers and are able to apply best practices from other industries to address the needs of our clients.
About The American Society of Gene & Cell Therapy (ASGCT)
The American Society of Gene & Cell Therapy (ASGCT) is the primary membership organization for scientists, physicians, professionals, and patient advocates involved in gene and cell therapy. Our mission is to advance knowledge, awareness, and education leading to discovery and clinical application of gene and cell therapies to alleviate disease—we do that by serving as a catalyst to transform medicine by advancing gene and cell therapies to benefit patients and society.
Read more: https://annualmeeting.asgct.org/am19/